Tata Consultancy Services unveiled TCS ADD AgentHub on August 17, an agentic AI platform aimed at scaling AI agents across drug development, clinical trials and pharmacovigilance.
In an exchange filing, India’s largest IT services firm said the platform targets trust, governance and scalability problems that keep pharma from deploying AI broadly. Growing data volumes, fragmented systems and stricter regulatory expectations have complicated the R&D value chain.
AgentHub gives agents defined roles, explicit oversight and built-in auditability, and lets companies deploy customized AI agent hubs across clinical workflows with minimal integration effort while staying compliant. TCS describes the approach as a Human + AI Operating Model, embedding agents into enterprise workflows rather than bolting them on.
The launch extends TCS’s agentic AI push into life sciences, where competitors including Cognizant and Accenture are also productizing agent platforms for regulated industries. For pharma teams, the pitch is narrower: agents that handle documentation-heavy safety and trial work under supervision, with records that stand up to inspection.
